Sanofi

News

Ablynx drug fails in mid-stage lupus trial

Ablynx’s vobarilizumab has failed in a mid-stage trial in lupus, with the biotech’s multi-billion buyout from Sanofi just around the corner.

Partner Content

Partner Content

Sanofi Joins the Speaker Line-up for SMi's Launch, Injectabl...

Injectable Drug Delivery

News

Sanofi passes on Alnylam's breakthrough therapy

Alnylam is to forge ahead with a rare disease therapy on its own after Sanofi decided to opt out of a co-development and co-marketing deal.

News

Double blow to Amgen with Sanofi's Praluent data and price c...

Sanofi and Regeneron have scored a major victory in their fight with Amgen in the market for cardiovascular drugs, after releasing data showing their Praluent injection reduces risk of card

News

Sanofi in talks with Evotec to out-licence antibiotic resear...

Evotec to collaborate with academia, pharma and biotech on new antimicrobials

News

FDA to review Sanofi's Dupixent in asthma

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema.

Ablynx drug fails in mid-stage lupus trial

Sanofi Joins the Speaker Line-up for SMi's Launch, Injectabl...

Sanofi passes on Alnylam's breakthrough therapy

Double blow to Amgen with Sanofi's Praluent data and price c...

Sanofi in talks with Evotec to out-licence antibiotic resear...

FDA to review Sanofi's Dupixent in asthma

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Sanofi

Editor's Picks